Literature DB >> 18408243

Real and expected delivery rates of patients with myotonic dystrophy undergoing intracytoplasmic sperm injection and preimplantation genetic diagnosis.

W Verpoest1, M De Rademaeker, K Sermon, M De Rycke, S Seneca, E Papanikolaou, C Spits, L Van Landuyt, J Van der Elst, P Haentjens, P Devroey, I Liebaers.   

Abstract

BACKGROUND: This study aimed to analyse the reproductive outcome of a large cohort of myotonic dystrophy type 1 (DM1) patients undergoing ICSI and PGD. The secondary outcome parameter of this study was ovarian response as a way to express gonadal function in female DM1 patients.
METHODS: Prospective cohort study. Real and expected cumulative delivery rates are descriptive. The reproductive outcome per cycle was compared with that of a control group of patients with X-linked recessive disorders. The comparative analysis of ovarian stimulation parameters in the study group versus the control group was carried out using both bivariate (crude) and multivariate (linear regression) analysis.
RESULTS: Between 1995 and 2005, 205 cycles of ICSI and PGD were carried out for DM1 in 78 couples. The real cumulative delivery rate (max 6 cycles) overall was 46%. The expected overall cumulative delivery rate was 72%. Multivariate analysis did not show a significant difference in total dose of gonadotrophins used for ovarian stimulation between Group A (in which the female partner was affected) and a control group.
CONCLUSIONS: This study shows that ICSI and PGD for DM1 offer good reproductive outcome, both in cumulative terms and per treatment cycle. There is no evidence of impaired gonadal function in female DM1 patients.

Entities:  

Mesh:

Year:  2008        PMID: 18408243     DOI: 10.1093/humrep/den105

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  The reproductive outcome of female patients with myotonic dystrophy type 1 (DM1) undergoing PGD is not affected by the size of the expanded CTG repeat tract.

Authors:  Willem Verpoest; Sara Seneca; Marjan De Rademaeker; Karen Sermon; Martine De Rycke; Michel De Vos; Patrick Haentjens; Paul Devroey; Ingeborg Liebaers
Journal:  J Assist Reprod Genet       Date:  2010-03-11       Impact factor: 3.412

Review 2.  The biology of infertility: research advances and clinical challenges.

Authors:  Martin M Matzuk; Dolores J Lamb
Journal:  Nat Med       Date:  2008-11-06       Impact factor: 53.440

3.  Preimplantation genetic diagnosis for myotonic dystrophy type 1: upon request to child.

Authors:  Marjan De Rademaeker; Willem Verpoest; Martine De Rycke; Sara Seneca; Karen Sermon; Sonja Desmyttere; Maryse Bonduelle; Josianne Van der Elst; Paul Devroey; Inge Liebaers
Journal:  Eur J Hum Genet       Date:  2009-04-15       Impact factor: 4.246

4.  The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study.

Authors:  Nicholas E Johnson; Man Hung; Eriko Nasser; Katharine A Hagerman; Wei Chen; Emma Ciafaloni; Chad R Heatwole
Journal:  J Neuromuscul Dis       Date:  2015-10-07

5.  Effect of polyvinylpyrrolidone on sperm function and early embryonic development following intracytoplasmic sperm injection in human assisted reproduction.

Authors:  Yoku Kato; Yoshikazu Nagao
Journal:  Reprod Med Biol       Date:  2012-04-10

Review 6.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

7.  Anti-Müllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies.

Authors:  Olesja Parmova; Eva Vlckova; Monika Hulova; Livie Mensova; Igor Crha; Petra Stradalova; Eva Kralickova; Lenka Jurikova; Martina Podborska; Radim Mazanec; Ladislav Dusek; Jiri Jarkovsky; Josef Bednarik; Stanislav Vohanka; Iva Srotova
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.